Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira(Princess Margaret Cancer Centre), Lisa K. Hicks(St. Michael's Hospital), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center), Fernando Martín‐Moro(Instituto Cajal), William A. Wood(University of North Carolina at Chapel Hill), Rushad Patell(Beth Israel Deaconess Medical Center), Ioannis Mantzaris(Montefiore Medical Center), Thomas A. Fox(University College London Hospitals NHS Foundation Trust), Lydia Scarfò(IRCCS Ospedale San Raffaele), Gordon Cook(University of Leeds), Halil Yıldız(Cliniques Universitaires Saint-Luc), Stephen Booth(Royal Berkshire Hospital), Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Bruno Fattizzo(University of Milan), Raphaël Lattenist(Cliniques Universitaires Saint-Luc), Marie Christiane Vekemans(Cliniques Universitaires Saint-Luc), John C. Riches(Queen Mary University of London), Jérôme Razanamahery(Université de Bourgogne), Inna Y. Gong(University of Toronto)
Cited by 657
Related Papers
Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
|Journal of Clinical Oncology|2022|608
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564